Komori
Financial results presentation4886ASKA Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

Supplementary Materials for the Third-Quarter Financial Results for the Fiscal Year Ending March 2026

Revenue for the cumulative third quarter increased 9.1% year on year, driven by contributions from the overseas business and other factors, reaching a record high. Operating profit, however, declined 10.6% year on year due to higher selling, general and administrative expenses, including research and development expenses.

Worth reading
80Important
Scored from 3 of 6 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
4560
¥ million (year-on-year increase in revenue)
Wording
Conditional
How definitive the wording is.

Contents of this document

Supplementary materials to the earnings reportFiscal year ending March 2026, third quarter4 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥54,486 million+9.1%
Operating profit¥4,911 million-10.6%
Ordinary income¥4,854 million-10.9%
Net income¥3,904 million-4.7%
Selling, general and administrative expenses¥21,400 million
Full-year earnings forecast
Net Sales
¥71,000 million
Operating profit
¥6,000 million
Ordinary income
¥6,000 million
Profit attributable to owners of the parent
¥5,000 million
What the company explained in this material
New initiatives
  • Hataphar社の連結子会社化に伴う海外事業セグメントの新設
  • AKP-022、LPRI-CF113、治療用アプリなどの研究開発を継続
Key KPIsA metric the company considers important as a management benchmark.
  • Ratio of sales from branded products57.1 %
    Year on year against the same period last year2.3ポイント増加
  • Research and development costs¥5,405 million
  • 医療用医薬品事業売上高¥45,332 million
    Year on year against the same period last year+2.9%
  • アニマルヘルス事業売上高¥5,759 million
    Year on year against the same period last year+1.0%
  • 動物用医薬品売上高¥2,109 million
    Year on year against the same period last year+0.2%
Unit price and quantity metricsThese figures show sales broken down by price and volume.
製品ごとに薬価・数量の増減要因を記載（数量の具体的な数値はNot disclosed）
Segment results
Prescription Pharmaceutical Business
Sales
¥45,332 million+2.9%
Profit/Loss
¥5,822 million-6.1%
Animal Health Business
Sales
¥5,759 million+1.0%
Profit/Loss
¥368 million+22.6%
Overseas Business
Sales
¥3,240 million
Profit/Loss
¥70 million
Other businesses
Sales
¥153 million-7.7%
Profit/Loss
¥-28 million
Contents of this document
ItemDetails
Document typeSupplementary materials to the earnings report
Fiscal Period CoveredFiscal year ending March 2026, third quarter
Net Sales¥54,486 million (YoY +9.1%)
Operating profit¥4,911 million (YoY -10.6%)
Ordinary income¥4,854 million (YoY -10.9%)
Net income¥3,904 million (YoY -4.7%)
Selling, general and administrative expenses¥21,400 million
Full-year earnings forecastNet Sales ¥71,000 million / Operating profit ¥6,000 million / Ordinary income ¥6,000 million / Profit attributable to owners of the parent ¥5,000 million
Segment resultsPrescription Pharmaceutical Business Sales ¥45,332 million (YoY +2.9%) / Profit/Loss ¥5,822 million (YoY -6.1%) / Animal Health Business Sales ¥5,759 million (YoY +1.0%) / Profit/Loss ¥368 million (YoY +22.6%) / Overseas Business Sales ¥3,240 million / Profit/Loss ¥70 million / Other businesses Sales ¥153 million (YoY -7.7%) / Profit/Loss ¥-28 million
Key KPIsIndicator name Ratio of sales from branded products / Value 57.1 % / Year on year against the same period last year 2.3ポイント増加, Indicator name Research and development costs / Value ¥5,405 million / Year on year against the same period last year Not disclosed, Indicator name 医療用医薬品事業売上高 / Value ¥45,332 million / Year on year against the same period last year ¥2.9 million, Indicator name アニマルヘルス事業売上高 / Value ¥5,759 million / Year on year against the same period last year ¥1 million, Indicator name 動物用医薬品売上高 / Value ¥2,109 million / Year on year against the same period last year ¥0.2 million
Unit price and quantity metrics製品ごとに薬価・数量の増減要因を記載（数量の具体的な数値はNot disclosed）
New initiativesHataphar社の連結子会社化に伴う海外事業セグメントの新設, AKP-022、LPRI-CF113、治療用アプリなどの研究開発を継続
Items this document does not state (19)
Gross Profit MarginOperating profit marginResults for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planBreakdown of Factors Affecting the ChangeNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

売上高は、医療用医薬品事業や動物用医薬品事業が堅調に推移したことに加え、海外事業が寄与した。利益は、研究開発費などの販管費が増加し、売上総利益の増加を上回ったため減少した。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Supplementary Materials for the Third-Quarter Financial Results for the Fiscal Year Ending March 2026 | ASKA Pharmaceutical Holdings Co.,Ltd. (4886) timely disclosure | Komori